

REMARKS

The rejections of Claims 1, 6, 9 and 14 under 35 U.S.C. § 102(b) as anticipated by, and of Claims 2-4 and 10-12 under 35 U.S.C. § 103(a) as unpatentable over, U.S. 5,115,037 (Asrar), are respectfully traversed. Asrar is drawn to saturated cyclopentanedicarboximide polymers, which polymers contain ethylene cyclopentanedicarboximide units. However, all the rejected claims now contain the limitations of Claim 5, not subject to these rejections. Accordingly, it is respectfully requested that the rejections be withdrawn.

The rejection of Claims 4 and 9-16 under 35 U.S.C. § 112, second paragraph, is respectfully traversed. Indeed, the rejection would now appear to be moot in view of the above-discussed amendment. Accordingly, it is respectfully requested that the rejection be withdrawn.

The objection to Claim 9 is now moot in view of the above-discussed amendment. Accordingly, it is respectfully requested that the objection be withdrawn.

Applicants respectfully call the Examiner's attention to the Information Disclosure Statement (IDS) filed August 17, 2006. The Examiner is respectfully requested to initial the Form PTO 1449 submitted therewith, and include a copy thereof with the next Office communication.

Application No. 10/534,003
Reply to Office Action of June 5, 2006

Applicants gratefully acknowledge the Examiner's indication of allowability of Claims 5, 7 and 8. Nevertheless, Applicants respectfully submit that all of the presently-pending claims in this application are now in immediate condition for allowance.

Accordingly, the Examiner is respectfully requested to pass this application to issue.

Respectfully submitted,


Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 06/04)

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon



Harris A. Pitlick

Registration No. 38,779

NFO:HAP\rl